HALOZYME THERAPEUTICS, INC.
Congressional Trades
Whale Activity
- Increased247
- New157
- Held95
- Decreased243
- Closed47
- No prior filing35
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 13.7M | $1.51B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1M | $563.8M | decreased |
| STATE STREET CORP | 5.1M | $559.0M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0M | $550.6M | decreased |
| Invesco Ltd. | 3.5M | $390.2M | increased |
| TWO SIGMA INVESTMENTS, LP | 3.5M | $388.5M | increased |
| D. E. Shaw & Co., Inc. | 3.4M | $372.4M | increased |
| MORGAN STANLEY | 2.9M | $314.7M | increased |
| Boston Partners | 2.8M | $305.1M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4M | $266.6M | decreased |
| BANK OF AMERICA CORP /DE/ | 2.4M | $262.0M | decreased |
| CONGRESS ASSET MANAGEMENT CO | 2.3M | $251.9M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Posard Matthew L.Director · Director | Sale | −3,400 | $96.17 | $327K | Nov 18, 2026 | Form 4 ↗ |
| Posard Matthew L.Director · Director | Sale | −1,600 | $96.97 | $155K | Nov 18, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −7,283 | $96.85 | $705K | Nov 16, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −4,897 | $100.10 | $490K | Nov 16, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −4,802 | $97.95 | $470K | Nov 16, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −188 | $101.72 | $19K | Nov 16, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −1,586 | $98.89 | $157K | Nov 16, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −1,244 | $101.06 | $126K | Nov 16, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −7,992 | $100.02 | $799K | Nov 13, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −12.0K | $100.61 | $1.2M | Nov 13, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −9,289 | $101.49 | $943K | Nov 12, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −10.7K | $101.09 | $1.1M | Nov 12, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −4,810 | $108.18 | $520K | Oct 8, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −3,090 | $108.91 | $337K | Oct 8, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −200 | $110.51 | $22K | Oct 8, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −11.9K | $110.00 | $1.3M | Oct 8, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −900 | $112.78 | $102K | Oct 7, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −8,600 | $111.03 | $955K | Oct 7, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −200 | $113.69 | $23K | Oct 7, 2026 | Form 4 ↗ |
| Torley HelenPRESIDENT AND CEO · Director | Sale | −10.3K | $111.84 | $1.2M | Oct 7, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 4.1M | $317.7M | 0.26% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.8M | $294.5M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.7M | $213.0M | 0.11% | Jun 30, 2026 |
| Invesco Discovery Fund AIM Counselor Series Trust (Invesco Counselor Series Trust) | 1.4M | $147.3M | 1.99% | Aug 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $122.6M | 0.26% | Jun 30, 2026 |
| Disciplined Value Mid Cap Fund John Hancock Funds III | 1.4M | $112.0M | 0.48% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.4M | $110.5M | 1.03% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $106.4M | 0.11% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 1.1M | $87.6M | 3.11% | Jun 30, 2026 |
| FULLERTHALER BEHAVIORAL SMALL-CAP GROWTH Capitol Series Trust | 968.8K | $75.8M | 1.23% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list HALO's shares (CUSIP 40637H109), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
- FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q3 · HCR, MMM$80K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q2 · MMM, HCR$80K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2026 Q1 · HCR, MMM$70K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2025 Q4 · HCR, MMM$60K
Filing ↗ - FORBES-TATEHALOZYME THERAPEUTICS, INC. · 2025 Q3 · HCR, MMM$60K
Filing ↗
Government Contracts
No federal contract awards found for HALOZYME THERAPEUTICS, INC..
U.S. Patents
No USPTO patent applications found for HALOZYME THERAPEUTICS, INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Cash and equivalents | $133.8M | $115.8M | $118.4M | $234.2M | $118.7M |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | n/a |
| Shareholders' equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M |
As HALOZYME THERAPEUTICS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 17, 2026 ↗
Stock Splits
No stock splits in HALO's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 30, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 9.01Material agreement · Direct financial obligation · Unregistered sale of equitySep 22, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 18, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 16, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeAug 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJul 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 7, 2026
EDGAR ↗




